ReviewNature reviews. Nephrology2015
Haemodialysis-induced hypoglycaemia and glycaemic disarrays.
Review in Nature reviews. Nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 181 citations in OpenAlex.
- Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta-analysis.Journal of diabetes investigation · 2022Pooled it
- Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study.Scientific reports · 2019Trial
- Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial.European journal of clinical nutrition · 2019Trial
- The angiotensin-I converting enzyme gene I/D variation contributes to end-stage renal disease risk in Chinese patients with type 2 diabetes receiving hemodialysis.Molecular and cellular biochemistry · 2016Trial
- An International Expert Consensus Statement and Guidance Document on Implementation of Nutritional Supplementation in Patients on Dialysis.Kidney international reports · 2026Article
- The use of automated insulin delivery system in people with type 1 diabetes and end stage kidney disease on hemodialysis.JCEM case reports · 2026Article
- Continuous Glucose Monitoring and Mortality Risk Among U.S. Veterans Receiving Dialysis With Diabetes.Diabetes care · 2026Article
- The effect of icodextrin on peritoneal dialysis patients with congestive heart failure: a time-varying exposure design and target trial emulation approach.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Glycemic Patterns Revealed by Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing Intermittent Hemodialysis: A Pilot Study.Medical sciences (Basel, Switzerland) · 2026Observational
- Continuous glucose monitoring reveals distinct clinical implications of glucose levels at the start and end of hemodialysis in people with type 2 diabetes.BMC endocrine disorders · 2026Article
- Continuous glucose monitoring (CGM) use in people living with diabetes on maintenance dialysis: a retrospective audit and observational cohort study.BMC nephrology · 2026Observational
- Factors Associated With Predialysis Plasma Glucose Variability in Patients With Diabetes on Hemodialysis.International journal of endocrinology · 2026Article
- Practical Use of Continuous Glucose Monitoring to Adjust Glucose-Lowering Therapy in Hemodialysis Patients: A Case Series.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Article
- Frequent hypoglycemia during hemodialysis in ESRD patients leads to higher risk of death.Renal failure · 2025Article
- Glucotypes in patients with type 2 diabetes and either diabetic kidney disease or end stage kidney disease under different anti-diabetic treatments.BMC endocrine disorders · 2025Article
- Using automated insulin delivery to address the clinical challenges of glycemic management in people with type 1 diabetes and kidney failure on maintenance hemodialysis.Journal of diabetes investigation · 2025Article
- Analysis of Factors Associated with Hypoglycemia in Patients with Out-of-Hospital Cardiac Arrest Undergoing Targeted Temperature Management.Journal of clinical medicine · 2025Article
- Scoping Review-Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions.Journal of diabetes science and technology · 2025Review
- Unraveling hypoglycemia risk during hemodialysis: a predictive model from a nested case-control study.Frontiers in physiology · 2025Article
- Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
In patients with diabetes receiving chronic haemodialysis, both very high and low glucose levels are associated with poor outcomes, including mortality. Conditions that are associated with an increased risk of hypoglycaemia in these patients include decreased gluconeogenesis in the remnant kidneys, deranged metabolic pathways, inadequate nutrition, decreased insulin clearance, glucose loss to the dialysate and diffusion of glucose into erythrocytes during haemodialysis. Haemodialysis-induced hypoglycaemia is common during treatments with glucose-free dialysate, which engenders a catabolic status similar to fasting; this state can also occur with 5.55 mmol/l glucose-containing dialysate. Haemodialysis-induced hypoglycaemia occurs more frequently in patients with diabetes than in those without. Insulin therapy and oral hypoglycaemic agents should, therefore, be used with caution in patients on dialysis. Several hours after completion of haemodialysis treatment a paradoxical rebound hyperglycaemia may occur via a similar mechanism as the Somogyi effect, together with insulin resistance. Appropriate glycaemic control tailored for patients on haemodialysis is needed to avoid haemodialysis-induced hypoglycaemia and other glycaemic disarrays. In this Review we summarize the pathophysiology and current management of glycaemic disarrays in patients on haemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.